Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.
CORT - Corcept Therapeutics Incorporated
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$83.00
DETAILS
HIGH:
$135.00
LOW:
$30.00
MEDIAN:
$91.50
CONSENSUS:
$83.00
UPSIDE:
3.87%
Stock News
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders.
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing's syndrome.As requested by t.
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
New York, New York--(Newsfile Corp. - June 16, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company's lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing's syndrome.
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.
CORT Stock Rises 42% in a Month: Here's What You Should Know
Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli approval to expand the company's revenue base.
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the presentation of new data from its CATALYST and MOMENTUM trials at the American Diabetes Association's 86th Scientific Sessions. The presentations underscore the critical role of.
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented new overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) plus nab-paclitaxel (a taxane chemotherapy) in an oral presentation at the ASCO 2026 (Ame.
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cushing's syndrome.
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it will resubmit its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing's syndrome. “Following issuan.
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade
The consensus price target hints at a 43.3% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?
Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.
Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint.
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
Corcept Q1 loss meets estimates, while revenues miss. The company boosts 2026 outlook as new drug Lifyorli and rising Korlym demand reshape growth trajectory.
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk
Corcept Therapeutics Inc. (NASDAQ:CORT) shares are up on Friday as the company reported significant findings from its Phase 2 DAZALS study, demonstrating an 87% reduction in the risk of death for patients with amyotrophic lateral sclerosis (ALS) compared to those receiving a placebo.
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Price Targets
H.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT)
$95.00
(was $70.44)
Swayampakula Ramakanth
·
H.C. Wainwright
Corcept Therapeutics price target raised to $135 from $110 at Canaccord
$135.00
(was $66.65)
UBS
Corcept Therapeutics upgraded to Buy from Neutral at UBS
$72.00
(was $51.16)
UBS
Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright
$75.00
(was $51.42)
H.C. Wainwright
Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler
$88.00
(was $46.52)
Piper Sandler
Corcept Therapeutics price target lowered to $67 from $105 at H.C. Wainwright
$67.00
(was $34.24)
H.C. Wainwright
Corcept Therapeutics price target raised to $100 from $99 at Canaccord
$100.00
(was $41.30)
Canaccord Genuity
Corcept Therapeutics price target raised to $105 from $90 at H.C. Wainwright
$105.00
(was $41.47)
Swayampakula Ramakanth
·
H.C. Wainwright
Corcept Therapeutics (CORT) PT Lowered to $90 at H.C. Wainwright
$90.00
(was $36.35)
Swayampakula Ramakanth
·
H.C. Wainwright
Corcept Therapeutics (CORT) PT Lowered to $99 at Canaccord Genuity
$99.00
(was $36.90)
Edward Nash
·
Canaccord Genuity
Corcept Therapeutics price target lowered to $50 from $135 at Truist
$50.00
(was $34.25)
Truist Financial
Corcept downgraded to Underperform at Wolfe after CRL for relacorilant
$30.00
(was $33.12)
Wolfe Research
Corcept Therapeutics initiated with a Neutral at UBS
$95.00
(was $87.30)
Ashwani Verma
·
UBS
Corcept Therapeutics price target raised to $140 from $137 at Canaccord
$140.00
(was $71.62)
Canaccord Genuity
Corcept Therapeutics price target lowered to $135 from $150 at Truist
$135.00
(was $70.74)
Joon Lee
·
Truist Financial
Corcept Therapeutics price target lowered to $145 from $150 at H.C. Wainwright
$145.00
(was $73.94)
Swayampakula Ramakanth
·
H.C. Wainwright
Corcept Therapeutics (CORT) PT Raised to $80 at H.C. Wainwright
$80.00
(was $47.17)
Swayampakula Ramakanth
·
H.C. Wainwright
Corcept Therapeutics price target raised to $76 from $65 at Truist
$76.00
(was $43.93)
Joon Lee
·
Truist Financial
Canaccord Genuity Reiterates Buy Rating on Corcept Therapeutics (CORT)
$78.00
(was $34.71)
Edward Nash
·
Canaccord Genuity
Corcept Therapeutics (CORT) PT Raised to $38 at Piper Sandler
$38.00
(was $36.12)
David Amsellem
·
Piper Sandler